

CANCER TREATMENT REGIMENS

Rare Cancers

Thymomas and Thymic Carcinomas

The selection, dosing, and administration of anticancer agents and the management of associated toxicities are complex. Drug dose modifications and schedule and initiation of supportive care interventions are often necessary because of expected toxicities and because of individual patient variability, prior treatment, and comorbidities. Thus, the optimal delivery of anticancer agents requires a healthcare delivery team experienced in the use of such agents and the management of associated toxicities in patients with cancer. These cancer treatment regimens may include both FDA-approved and unapproved uses/regimens and are provided as references only to the latest treatment strategies. Clinicians must choose and verify treatment options based on the individual patient.

NOTE: Grey shaded boxes contain updated regimens.

THYMOMAS AND THYMIC CARCINOMAS

REGIMEN	DOSING
First-Line Combination Regimens	
Carboplatin (Paraplatin) + paclitaxel (Taxol) ^{1,2} *Preferred regimen	Carboplatin AUC=5mg/mL/min IV + paclitaxel 225mg/m ² IV. Repeat cycle every 3 weeks for max 6 cycles.
CAP (cisplatin [Platinol; CDDP] + doxorubicin [Adriamycin] + cyclophosphamide [Cytosan]) ^{1,3}	Day 1: Cisplatin 50mg/m ² IV + doxorubicin 50mg/m ² IV + cyclophosphamide 500mg/m ² IV. Repeat cycle every 3 weeks for max 8 cycles.
CAP + prednisone ^{1,4}	Day 1: Cyclophosphamide 500mg/m ² IV, plus Days 1-3: Cisplatin 30mg/m ² IV + doxorubicin 20mg/m ² continuous IV infusion, plus Days 1-5: Prednisone 100mg/day. Repeat cycle every 3 weeks for 3 cycles.
VIP (etoposide [Toposar, VePesid, Etopophos; VP-16] + ifosfamide [Ifex] + cisplatin) ^{1,5}	Days 1-4: Etoposide 75mg/m ² IV + ifosfamide 1,200mg/m ² IV + cisplatin 20mg/m ² IV. Repeat cycle every 3 weeks for 4 cycles.
ADOC (cisplatin + doxorubicin + cyclophosphamide + vincristine [Oncovin; VCR]) ^{1,6}	Day 1: Cisplatin 50mg/m ² IV + doxorubicin 40mg/m ² IV, followed by Day 3: Vincristine 0.6mg/m ² IV, followed by Day 4: Cyclophosphamide 700mg/m ² IV. Repeat cycle every 4 weeks.
PE (cisplatin + etoposide [Toposar, VePesid, Etopophos; VP-16]) ^{1,7}	Day 1: Cisplatin 60mg/m ² IV, plus Days 1-3: Etoposide 120mg/m ² /day IV. Repeat cycle every 3 weeks.
Second-Line Chemotherapy	
Enrollment in clinical trials is encouraged and may include these therapies	Etoposide Ifosfamide Pemetrexed (Alimta) Octreotide (Sandostatin) ± prednisone 5-fluorouracil (5-FU) + leucovorin Gemcitabine (Gemzar) Paclitaxel
References	
<ol style="list-style-type: none"> 1. NCCN Clinical Practice Guidelines in Oncology™. Thymomas and Thymic Carcinomas. v 1.2012. Available at: http://www.nccn.org/professionals/physician_gls/pdf/thymic.pdf. Accessed October 16, 2011. 2. Lemma GL, Loehrer PJ, Lee JW, Langer CJ, Tester WJ, Johnson DH. A phase II study of carboplatin plus paclitaxel in advanced thymoma or thymic carcinoma: E1C99. <i>J Clin Oncol</i>. 26:2008 (May 20 suppl; abstr 8018). 3. Loehrer PJ Sr, Kim K, Aisner SC, et al. Cisplatin plus doxorubicin plus cyclophosphamide in metastatic or recurrent thymoma: final results of an intergroup trial. The Eastern Cooperative Oncology Group, Southwest Oncology Group, and Southeastern Cancer Study Group. <i>J Clin Oncol</i>. 1994;12:1164-1168. 4. Kim ES, Putnam JB, Komaki R, et al. Phase II study of a multidisciplinary approach with induction chemotherapy, followed by surgical resection, radiation therapy, and consolidation 	<ol style="list-style-type: none"> chemotherapy for unresectable malignant thymomas: final report. <i>Lung Cancer</i>. 2004;44:369-79. 5. Loehrer PJ Sr, Jiroutek M, Aisner S, et al. Combined etoposide, ifosfamide, and cisplatin in the treatment of patients with advanced thymoma and thymic carcinoma: an intergroup trial. <i>Cancer</i>. 2001;91:2010-2015. 6. Fornasiero A, Daniele O, Ghiotto C, Piazza M, Fiore-Donati L, Calabró F, Rea F, Fiorentino MV. Chemotherapy for invasive thymoma. A 13-year experience. <i>Cancer</i>. 1991;68:30-33. 7. Giaccone G, Ardizzoni A, Kirkpatrick A, Clerico M, Sahnoud T, van Zandwijk N. Cisplatin and etoposide combination chemotherapy for locally advanced or metastatic thymoma. A phase II study of the European Organization for Research and Treatment of Cancer Lung Cancer Cooperative Group. <i>J Clin Oncol</i>. 1996; 14:814-820.
(Revised 11/2011) Copyright © 2011 by Haymarket Media Inc.	